Cayuga's CAY001 Significantly Increases Survival and Improves Bleeding Outcomes in Platelet Inhibitor-Related Bleeding
Data on CAY001, a First-in-Class, Polyphosphate (polyP)-Based Therapy, Show Promise in Bypassing P2Y12 Inhibition to Restore Normal Clotting Function NEW YORK, NY, UNITED STATES, March 29, 2025 /EINPresswire.com/ -- Cayuga Biotech, a company …